NGM·Healthcare·$34M·#453 / 520 in Healthcare

ACTU Actuate Therapeutics, Inc.

23HIGH RISK

CATEGORY BREAKDOWN

GROWTH0
QUALITY0
STABILITY31
VALUATION50
GOVERNANCE56

METRIC BREAKDOWN

Revenue Growth (YoY)

Year-over-year revenue growth rate

N/A
0

> 50% strong

Gross Margin

Revenue retained after direct costs

N/A
0

> 50% strong

Cash Runway

Months of cash at current burn rate

8 months
21

> 24 months ideal

Debt / Equity

Total debt relative to shareholder equity

N/A
50

< 25% strong

Price / Sales

Market cap relative to trailing revenue

N/A
50

< 3x strong

Rule of 40

Growth rate plus operating margin

N/A
0

> 40 excellent

Insider Ownership

Percentage of shares held by insiders

14.8%
75

> 20% strong

Share Dilution (12M)

Share count increase over last 12 months

+16.9%
19

< 5% ideal

SCORE HISTORY

COMPARE ACTU WITH…

ACTUvs

OR QUICK-COMPARE SECTOR PEERS

SCORE ALERT

Get notified when ACTU's score changes by 5+ points.

DATA INFO

Last updated: Jul 1, 2026

Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.